Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b studyLecia V. Sequist, Geoffrey R. Oxnard, Lone H. Ottesen et al.|The Lancet Oncology|2020Cited by 413
Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein–Overexpressing Advanced Nonsquamous <i>EGFR</i> -Wildtype Non–Small Cell Lung Cancer in the Phase II LUMINOSITY TrialD. Ross Camidge, Shun Lü, Jair Bar et al.|Journal of Clinical Oncology|2024Cited by 131
Hypoxia-inducible Factor 1α and Antiangiogenic Activity of Farnesyltransferase Inhibitor SCH66336 in Human Aerodigestive Tract CancerJi‐Youn Han, Ho‐Young Lee|JNCI Journal of the National Cancer Institute|2005Cited by 97
Association of PD-L1 Expression with Tumor-Infiltrating Immune Cells and Mutation Burden in High-Grade Neuroendocrine Carcinoma of the LungHye Sook Kim, Ji‐Youn Han|Journal of Thoracic Oncology|2018Cited by 82
Integrative analysis of risk factors for immune-related adverse events of checkpoint blockade therapy in cancerChanghwan Sung, Sook Ryun Park, Jinhyeon An et al.|Nature Cancer|2023Cited by 46